Martinez-Rivas Gemma, Ayala Maria Victoria, Bender Sebastien, Codo Gilles Roussine, Swiderska Weronika Karolina, Lampis Alessio, Pedroza Laura, Merdanovic Melisa, Sicard Pierre, Pinault Emilie, Richard Laurence, Lavatelli Francesca, Giorgetti Sofia, Canetti Diana, Rinsant Alexa, Kaaki Sihem, Ory Cécile, Oblet Christelle, Pollet Justine, Naser Eyad, Carpinteiro Alexander, Roussel Muriel, Javaugue Vincent, Jaccard Arnaud, Bonaud Amélie, Delpy Laurent, Ehrmann Michael, Bridoux Frank, Sirac Christophe
CNRS UMR7276/INSERM U1262, University of Limoges, CRIBL lab, team 3 BioPIC, Limoges, France.
French National Reference Centre for AL Amyloidosis and Other Monoclonal IG Deposition Diseases, University Hospital, Limoges, France.
Nat Commun. 2025 Mar 27;16(1):2992. doi: 10.1038/s41467-025-58307-2.
Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better understanding this disease. Here, we develop a transgenic mouse model producing a human AL LC. We show that the soluble full length LC is not toxic but a single injection of pre-formed amyloid fibrils or an unstable fragment of the LC leads to systemic amyloid deposits associated with early cardiac dysfunction. AL fibrils in mice are highly similar to that of human, arguing for a conserved mechanism of amyloid fibrils formation. Overall, this transgenic mice closely reproduces human cardiac AL amyloidosis and shows that a partial degradation of the LC is likely to initiate the formation of amyloid fibrils in vivo, which in turn leads to cardiac dysfunction. This is a valuable model for research on AL amyloidosis and preclinical evaluation of new therapies.
免疫球蛋白轻链(LC)淀粉样变性(AL)是最常见的系统性淀粉样变性类型之一,但目前尚无可靠的体内模型来更好地理解这种疾病。在此,我们构建了一种产生人AL LC的转基因小鼠模型。我们发现可溶性全长LC无毒,但单次注射预先形成的淀粉样纤维或LC的不稳定片段会导致与早期心脏功能障碍相关的系统性淀粉样沉积。小鼠体内的AL纤维与人的高度相似,这表明淀粉样纤维形成机制具有保守性。总体而言,这种转基因小鼠能密切重现人类心脏AL淀粉样变性,并表明LC的部分降解可能在体内引发淀粉样纤维的形成,进而导致心脏功能障碍。这是用于AL淀粉样变性研究和新疗法临床前评估的有价值模型。